SA research helps upend decades of medical orthodoxy on deadly Golden Staph breakthrough.
Vital evidence generated by South African clinicians has helped upend decades of international medical orthodoxy, identifying safer and far more effective antibiotic treatments for life-threatening golden staph bloodstream infections.
Data from Johannesburg’s Helen Joseph Hospital, the only site from a low- and middle-income nation involved in the global SNAP Trial, has proved that the long-standing standard drug, flucloxacillin, should no longer be the default treatment for this lethal condition. Instead, researchers discovered that two alternative antibiotics, cefazolin and benzylpenicillin, offer significantly better survival rates and drastically lower the risk of severe organ damage, a breakthrough set to save thousands of lives globally every year.
Golden staph, or Staphylococcus aureus, is a devastating bacterium responsible for more than one million deaths annually worldwide. Its most lethal form occurs when the bacteria enter the bloodstream, resulting in a terrifying mortality rate of 15 to 25 percent. The burden of this disease is disproportionately carried by low- and middle-income nations like South Africa, where high disease burden intersects with resource-constrained healthcare systems. Despite the availability of various treatments, clinicians have spent decades plagued by uncertainty regarding which specific antibiotic strategies yield the absolute best outcomes for critically ill patients.
